Immunosuppression for pancreas transplantation

Current Opinion in Organ Transplantation

Volumn 10, Issue 2, 2005, Pages 169-175

  Kaufman, Dixon B ^a   Salvalaggio, Paolo R O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Immunosuppression; Induction; Maintenance; Minimization; Pancreas transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG SAFETY; DRUG TOXICITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; PANCREAS TRANSPLANTATION; PUBLICATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 21044437343     PISSN: 10872418     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mot.0000163354.35188.01     Document Type: Review

References (29)

1. Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4(Suppl 9):38-53. This is an excellent and comprehensive review on immunosuppression protocols.
2. http://www.optn.org.
3. http://www.iptr.umn.edu.
4. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of May 2003. Clin Transpl 2003; 21-51.
5. Stratta RJ, Lo A, Shokouh-Amiri MH, et al. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobin induction, and tacrolimus/mycophenolate mofetil-based immunosuppression. Transpl Int 2003; 16:154-160.
6. Chow FY, Polkinghorne K, Saunder A, et al. Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. Nephrol 2003; 8:212-216.
7. Rigotti P, Baldan N, Cadrobbi R, et al. Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. Transplant Proc 2002; 34:1906-1908.
8. Stratta RJ, Alloway RR, Lo A, et al. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003; 75:1260-1266.
9. Kaufman DB, Burke GW, Bruce DS, et al. Prospective, randomized, multicenter trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3:855-864.
10. Burke GW, Kaufman DB, Millis JM, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77:1269-1275. This is the latest publication of a multicenter randomized trial reporting benefits with the use of induction therapy for SPK transplantation.
11. Boggi U, Vistoli F, Del Chiaro M, et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Proc 2004; 36:1064-1066. The authors report on a single-center randomized trial that was not able to demonstrate difference in the use of tacrolimus or cyclosporine in SPK transplantation.
12. Bechstein WO, Malaise J, Saudek F, et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004; 77:1221-1228. This is a report of a multicenter randomized trial (The EuroSPK Study Group) that demonstrated advantage with the use of tacrolimus over cyclosporine in SPK transplantation.
13. Dieterle CD, Schmauss S, Veitenhansl M, et al. Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004; 77:1561-1565. Concerning glucose metabolism and secretory capacity of the pancreas graft, no significant differences were found comparing tacrolimus vs. cyclosporine.
14. Merion RM, Henry ML, Melzer JS, et al. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:105-111.
15. Odorico JS, Pirsch JD, Knechtle SJ, et al. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998; 66:1751-1759.
16. Garcia VD, Keitel E, Santos AF, et al. Immunosuppression in pancreas transplantation: mycophenolate mofetil versus sirolimus. Transplant Proc 2004; 36:975-977. The authors report a small series of patients that use sirolimus for maintenance in SPK transplantation. It reviews the world experience in the use of this agent for pancreas transplantation.
17. Knight RJ, Kerman RH, Zela S, et al. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation. Transplantation 2003; 75:1301-1306.
18. Kaufman DB, Leventhal JR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/ mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2002; 73: 169-177.
19. Kaufman DB, Leventhal JR, Gallon LG, et al. Technical and immunologic progress in simultaneous pancreas-kidney transplantation. Surgery 2002; 132:545-553.
20. Jordan ML, Chakrabarti P, Luke PP, et al. Steroid withdrawal for pancreas transplants under tacrolimus immunosuppression. Transplant Proc 2001; 33:1655.
21. Gruessner RW, Sutherland DE, Parr E, et al. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc 2001; 33:1663-1664.
22. Kahl A, Bechstein WO, Lorenz F, et al. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil. Transplant Proc 2001; 33:1694-1695.
23. Cantarovich D. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids. J Nephrol 2004; 17 (Suppl 8):S40-S46. This is a single-center study showing positive results with the use of rapid discontinuation and steroid withdrawal in pancreas transplantation.
24. Cantarovich D, Karam G, Giral M, et al. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation: A prospective and randomized study. In: ATC; Boston, MA: Am J Transplantation 2004; 4(Suppl 8):562. Interesting results are presented of a single-center study showing positive results with the use of rapid discontinuation and steroid withdrawal in pancreas transplantation.
25. Kaufman DB, Leventhal JR, Gallon LG, et al. Reduction of CMV disease with steroid-free immunossupression in SPK transplant recipients. In: ATC 2004; Boston, MA: Am J Transplantation 2004; 4(Suppl 8):562.
26. Wiland AM, Philosophe B, Weir MR. Steroid withdrawal improves one-year outcomes in solitary pancreas transplantaion. In: ATC 2004; Boston, MA: Am J Transplantation 2004; 4(Suppl 8):562. This is a report of a single-center study showing excellent short-term results with steroid withdrawal in solitary pancreas transplantation.
27. Luzi L, Picena Sereni L, Battezzati A, et al. Metabolic effects of a corticosteroid-free immunosuppressive regimen in recipients of pancreatic transplant. Transplantation 2003; 75:2018-2023.
28. Freise CE, Kang SM, Feng S, et al. Excellent short-term results with steroid-free maintenance immunosuppression in low-risk simultaneous pancreas-kidney transplantation. Arch Surg 2003; 138:1121-1125.
29. Gruessner R, Humar A, Kandaswamy R, et al. Conversion to a calcineurin inhibitor and steroid free regimen after pancreas transplantation. In: ATC; Boston, MA: Am J Transplantation; 2004, 4(Suppl 8): 561.